Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
Summary
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to upadacitinib prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
Key Details
Gender
All
Age Range
Any - Any
Study Type
EXPANDED_ACCESS
Enrollment
Not specified
Start Date
Not specified
Completion Date
Not specified
Last Updated
2026-08-20
Healthy Volunteers
No
Conditions
Crohn DiseaseUlcerative ColitisIdiopathic Arthritis (Including sJIA, pJIA, or JPsA)Atopic DermatitisRheumatoid ArthritisPsoriatic ArthritisAxial SpondyloarthritisNon-radiographic AxialSpondyloarthritisGiant Cell ArteritisSystemic Lupus ErythematosusAlopecia AreataNon Segmental VitiligoHidradenitis Suppurativa
Interventions
DRUG
Upadacitinib
Upadacitinib will be administered as oral solution.